恶性肿瘤免疫治疗疗效影像学评估现状

Current Status of Imaging Assessment of Cancer Response to Immunotherapy

免疫检查点抑制剂已成为肿瘤治疗领域最具潜力的新型疗法。免疫治疗应答模式与传统细胞毒性治疗不同,可能会表现出延迟反应、假性进展或超进展等,传统的实体瘤疗效评价标准(RECIST)难以识别新型治疗反应模式,从而低估免疫治疗疗效。因此,一系列针对免疫治疗的疗效评估标准,如实体瘤免疫疗效评价标准(iRECIST)等应运而生。本文就近年来影像学在免疫治疗疗效评价标准方面的研究进展与应用作一综述。

Immune checkpoint inhibitors have already been the promising novel treatment of cancer therapy.The response pattern of immunotherapy is different from that of traditional cytotoxic therapies and may present delayed response,pseudoprogression or hyperprogression.Traditional RECIST is difficult to identify new treatment response patterns,thus underestimating the efficacy of immunotherapy.Therefore,a series of criteria for evaluating the efficacy of immunotherapy,such as iRECIST,emerged.This paper reviews the recent progress and application of imaging methods in the evaluation criteria of immunotherapy efficacy.